Sanofi’s hyaluronic acid product lines, Synvisc and Synvisc-One, posted revenue of USD $76.4.1MM in 1Q19, flat vs. 1Q18.
U.S. revenue loss diminished from 2018, -2.2% vs. 1Q18 Emerging markets were strong, with +15.4% revenue vs. last year
Synvisc and Synvisc-One sales on an as-reported basis are as follows ($MM).
1Q19 1Q18 % Chg % Chg Orthobiologics $76.4 $76.4 $0.0 0.0%
Synvisc and Synvisc-One sales by geographic region are as follows ($MM).
Geographic Region 1Q19 1Q18 % Chg % Chg US $49.4 $50.6 -$1.1 -2.2% Ex-US $27.0 $25.8 $1.1 4.3% Europe $6.7 $6.7 $0.0 0.0% Emerging Markets $16.9 $14.6 $2.2 15.4% Rest of World $3.4 $4.5 -$1.1 -25.0% Total $76.4 $76.4 $0.0 0.0%
Sources: Sanofi
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email .
Favorite
Sanofi’s hyaluronic acid product lines, Synvisc and Synvisc-One, posted revenue of USD $76.4.1MM in 1Q19, flat vs. 1Q18.
U.S. revenue loss diminished from 2018, -2.2% vs. 1Q18
Synvisc and Synvisc-One sales on an as-reported basis are as follows...
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
